News & Updates

Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.

A stool-based microbial diagnostic test outperforms faecal immunochemical test (FIT) in detecting colorectal cancer (CRC) or advanced adenoma (polyps) in a study conducted in Hong Kong, Singapore and Japan.